Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-835 and BRII-179 Combination Therapy in Chronic Hepatitis B
NCT04749368Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Conjugated siRNA, Recombinant Protein Vaccines, Chemically Modified siRNA
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of elebsiran and BRII-179 in Chronic Hepatitis B (CHB) (3 cohorts), sponsored by Brii Biosciences. Primary endpoints: Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI Withdrawal, Number of Participants With Adverse Events (AE) and 2 more. Started Apr 2021; status: completed.
02
Drugs
elebsiranBRII-179
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04749368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749368.